Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
Dimethylcurcumin
Другие языки:

    Dimethylcurcumin

    Подписчиков: 0, рейтинг: 0
    Dimethylcurcumin
    Dimethylcurcumin.svg
    Clinical data
    Other names ASC-J9; GO-Y025
    Routes of
    administration    		 Topical
    Drug class Nonsteroidal antiandrogen; Selective androgen receptor degrader
    Identifiers
    • (1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C23H24O6
    Molar mass 396.439 g·mol−1
    3D model (JSmol)
    • COC1=C(C=C(C=C1)/C=C/C(=C/C(=O)/C=C/C2=CC(=C(C=C2)OC)OC)/O)OC
    • InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-15,24H,1-4H3/b9-5+,10-6+,18-15-
    • Key:ZMGUKFHHNQMKJI-CIOHCNBKSA-N

    Dimethylcurcumin (development code ASC-J9) is a nonsteroidal antiandrogen and a synthetic curcuminoid which is under development by AndroScience Corporation as a topical medication for the treatment of acne vulgaris. It has also been under investigation for the treatment of male pattern hair loss, spinal muscular atrophy, and wounds, but no development has been reported for these indications. There has been interest in the drug for the potential treatment of prostate cancer as well. As of 2017, it is in phase II clinical trials for acne vulgaris.

    Dimethylcurcumin is an androgen receptor (AR) inhibitor and shows strong and specific antiandrogenic activity in vitro (e.g., against LNCaP cell growth) at sufficiently high concentrations. However, its mechanism of action and effects differ from those of conventional antiandrogens; it is not an antagonist of the AR and instead appears to act as a selective degradation enhancer (SARD) of certain subpopulations of the AR, for instance those present in the prostate gland.

    See also



    Новое сообщение